GoKawiilPharma firms continue psychedelic drug research despite trial setbacks
Several pharmaceutical companies are continuing to invest in psychedelic compounds as potential treatments for mental-health conditions, even after some clinical trials have produced disappointing results. Separately, researchers are expanding longevity science beyond humans, testing repurposed drugs and new gene therapies to extend lifespan and treat age-related conditions in pets such as dogs and cats.